Five EU states suspend the vaccine Kosovo is expected to take after blood coagration cases

Four other states -- Luxembourg, Estonia, Lithuania and Latvia -- also suspended the use of this vaccine in order to provide time for a European Drug Agency commission to conduct investigations.

European drug regulator said that according to preliminary research, the vaccine group in Austria is unlikely to have been linked to the death of a 49-year-old nurse who received the AstraZeneca vaccine, writes The Guardian, broadcast Express.

With this vaccine, which will be produced by the “Serum” in India, Kosovo is expected to be supplied, but it is not known when exactly the first doses will reach. These doses in Kosovo are expected to arrive as part of the COVAX programme.

The nurse died in Austria from multiple blood clots in blood vessels ten days after being vaccinated, the European Drug Agency reported.

Another patient was diagnosed with pulmonary embolism, which produces blockades in lung arteries, but her condition is improving.

By Tuesday, two more cases of coagulating patients have been identified by the group that received the same doses of vaccines.

The European agency said that for now there is no evidence that vaccine has caused these health problems in patients, and that thrombosis is not on the list of possible side effects of the vaccine.

According to the agency, part of the vaccine group used in Austria is one million doses that have been distributed into 17 European Union states.